Rituximab

Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.[3] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers.[3][4][5][6] It is given by slow injection into a vein.[3]

Rituximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD20
Clinical data
Trade namesRituxan, MabThera, Truxima, others[1]
Other namesrituximab-abbs, rituximab-pvvr
AHFS/Drugs.comMonograph
MedlinePlusa607038
License data
Pregnancy
category
  • AU: C [2]
  • US: N (Not classified yet) [2]
    Routes of
    administration    		Intravenous infusion
    Drug classMonoclonal antibody
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • US: ℞-only
    • EU: Rx-only
    Pharmacokinetic data
    Bioavailability100% (IV)
    Elimination half-life30 to 400 hours (varies by dose and length of treatment)
    ExcretionUncertain: may undergo phagocytosis and catabolism in RES
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.224.382
    Chemical and physical data
    FormulaC6416H9874N1688O1987S44
    Molar mass143860.04 g·mol−1
     NY (what is this?)  (verify)

    Common side effects, which often occur within two hours of the medication being given, include rash, itchiness, low blood pressure, and shortness of breath.[3] Other severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal leukoencephalopathy, and toxic epidermal necrolysis.[3][7] It is unclear if use during pregnancy is safe for the baby.[3][2]

    Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.[8] When it binds to this protein it triggers cell death.[3]

    Rituximab was approved for medical use in 1997.[8] It is on the World Health Organization's List of Essential Medicines.[9] The patent expired in 2016, and a number of biosimilars have been launched.[10]

    Medical uses

    Rituximab destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases which are characterized by having too many B cells, overactive B cells, or dysfunctional B cells.

    Rituximab is used in combination with fludarabine and cyclophosphamide to treat previously untreated and previously treated CD20-positive chronic lymphocytic leukemia.[11] Rituximab is used in combination with methotrexate to treat moderately-to severely-active rheumatoid arthritis with inadequate response to one or more TNF antagonist therapies.[11] Rituximab is used in combination with glucocorticoids to treat both granulomatosis with polyangiitis and microscopic polyangiitis.[11]

    Rituximab in combination with hyaluronidase human, sold under the brand names MabThera SC and Rituxan Hycela,[12] is used to treat follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.[13]

    Blood cancers

    Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and lymphocyte predominant subtype, of Hodgkin's Lymphoma.[14] This also includes Waldenström's macroglobulinemia a type of NHL.[3]

    Autoimmune diseases

    Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease.[15] In the United States, it has been FDA-approved for use in combination with methotrexate (MTX) for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-TNF-alpha therapy. In Europe, the license is slightly more restrictive: it is licensed for use in combination with MTX in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy.[16]

    There is some evidence for efficacy, but not necessarily safety, in a range of other autoimmune diseases, and rituximab is widely used off-label to treat difficult cases of multiple sclerosis,[17][18] systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy and autoimmune anemias.[19] The most dangerous, although among the most rare, side effect is progressive multifocal leukoencephalopathy (PML) infection, which is usually fatal; however only a very small number of cases have been recorded occurring in autoimmune diseases.[19][20]

    Other autoimmune diseases that have been treated with rituximab include autoimmune hemolytic anemia, pure red cell aplasia, thrombotic thrombocytopenic purpura (TTP),[21] idiopathic thrombocytopenic purpura (ITP),[22][23] Evans syndrome,[24] vasculitis (e.g., granulomatosis with polyangiitis), bullous skin disorders (for example pemphigus, pemphigoid—with very encouraging results of approximately 85% rapid recovery in pemphigus, according to a 2006 study),[25] type 1 diabetes mellitus, Sjögren syndrome, anti-NMDA receptor encephalitis and Devic's disease,[26] Graves' ophthalmopathy,[27] autoimmune pancreatitis,[28] Opsoclonus myoclonus syndrome (OMS),[29] and IgG4-related disease.[30] There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases.[31]

    Organ transplants

    Rituximab is being used off-label in the management of kidney transplant recipients. This drug may have some utility in transplants involving incompatible blood groups. It is also used as induction therapy in highly sensitized patients going for kidney transplantation. The use of rituximab has not been proven to be efficacious in this setting and like all depleting agents, carries with it the risk of infection.

    Adverse events

    Serious adverse events, which can cause death and disability, include:[11][3]

    Two patients with systemic lupus erythematosus died of progressive multifocal leukoencephalopathy (PML) after being treated with rituximab. PML is caused by activation of JC virus, a common virus in the brain which is usually latent. Reactivation of the JC virus usually results in death or severe brain damage.[35]

    At least one patient with rheumatoid arthritis developed PML after treatment with rituximab.[36]

    Rituximab has been reported as a possible cofactor in a chronic Hepatitis E infection in a person with lymphoma. Hepatitis E infection is normally an acute infection, suggesting the drug in combination with lymphoma may have weakened the body's immune response to the virus.[37]

    Mechanisms of action
    Rituximab mechanisms of action; the three major independent mechanisms are (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement mediated cytotoxicity (CMC), and (3) apoptosis; subset panel illustrates a schematic view of CD20 structure and rituximab.[38]
    Rituximab binding to CD20. The CD20 proteins are sticking out of the cell membrane, and rituximab, the Y-shaped antibody, is binding to the CD20 proteins.

    The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in differentiation, but it is absent on terminally differentiated plasma cells. Although the function of CD20 is unknown, it may play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration and allowing activation of B cells.

    Rituximab is relatively ineffective in elimination of cells with low CD20 cell-surface levels. It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of the cap changes the effectiveness of natural killer (NK) cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this asymmetric protein cluster, it was killed only 40% of the time.[39][40]

    The following effects have been found:[41]

    The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.

    Rituximab binds to amino acids 170-173 and 182-185 on CD20, which are physically close to each other as a result of a disulfide bond between amino acids 167 and 183.[42]

    History

    Rituximab was developed by researcher Nabil Hanna and coworkers at IDEC Pharmaceuticals under the name IDEC-C2B8. The U.S. patent for the drug was issued in 1998 and expired in 2015.[43]

    Based on its safety and effectiveness in clinical trials,[44] rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens.[45] Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.[46] In 2010, it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma.[47]

    Rituximab is currently co-marketed by Biogen and Genentech in the U.S., by Hoffmann-La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran.

    It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[9]

    In 2014 Genentech reclassified rituxan as a specialty drug, a class of drugs that are only available through specialty distributors in the US.[48] Because wholesalers discounts and rebates no longer apply, hospitals would pay more.[48]

    Originally available for intravenous injection (e.g. over 2.5 hrs), in 2016 it gained EU approval in a formulation for subcutaneous injection for CLL.[49]

    Patents on the drug in expired in Europe in February 2013 and in the US in September 2016.[50] By November 2018, several biosimilars had been approved in the US, India, the European Union, Switzerland, Japan and Australia.[51][50][52]

    Research

    Chronic fatigue syndrome

    Rituximab did not improve symptoms in patients with chronic fatigue syndrome in a trial published in 2019.[53][54] 22% of participants had serious events.[53] This potential use was investigated after improvements in chronic fatigue syndrome was seen in two cancer patients treated with rituximab.[55]

    Intrathecal

    For CNS diseases, rituximab could be administered intrathecally and this possibility is under study.[56]

    Other anti-CD20 monoclonals

    The efficacy and success of Rituximab has led to some other anti-CD20 monoclonal antibodies being developed:

    • ocrelizumab, humanized (90%-95% human) B cell-depleting agent.
    • ofatumumab (HuMax-CD20) a fully human B cell-depleting agent.[57]
    • Third-generation anti-CD20s such as obinutuzumab have a glycoengineered Fc fragment (Fc)[58] with enhanced binding to Fc gamma receptors, which increase ADCC (antibody-dependent cellular cytotoxicity).[59] This strategy for enhancing a monoclonal antibody's ability to induce ADCC takes advantage of the fact that the displayed Fc glycan controls the antibody's affinity for Fc receptors.[60]
    gollark: Not much, robots are slow and underpowered.
    gollark: RFTools energy shields are pretty strong defenses, lots of things won't even teleport through them.
    gollark: Impressive.
    gollark: Oh wow.
    gollark: The only time I had forcefield issues was when I had a wither contained in one running off a power supply which was *really* not rated for that, which caused a minor wither containment breach.

    References
    1. Drugs.com International brand names for rituximab Archived 2016-04-22 at the Wayback Machine Page accessed 1 April 2016
    2. "Rituximab Use During Pregnancy". Drugs.com. 16 December 2019. Retrieved 2 February 2020.
    3. "Rituximab". The American Society of Health-System Pharmacists. Archived from the original on 27 March 2016. Retrieved 8 December 2016.
    4. Tandan, Rup; Hehir, Michael K.; Waheed, Waqar; Howard, Diantha B. (August 2017). "Rituximab treatment of myasthenia gravis: A systematic review". Muscle & Nerve. 56 (2): 185–196. doi:10.1002/mus.25597. ISSN 1097-4598. PMID 28164324.
    5. Singer, O; McCune, WJ (May 2017). "Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis". Current Opinion in Rheumatology. 29 (3): 248–253. doi:10.1097/BOR.0000000000000382. PMID 28306595.
    6. Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). "EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts". Pathogens (Basel, Switzerland). 7 (1): 28. doi:10.3390/pathogens7010028. PMC 5874754. PMID 29518976.
    7. "Boxed Warning and new recommendations to decrease risk of hepatitis B". U.S. Food and Drug Administration (FDA). 13 January 2017. Retrieved 2 February 2020.
    8. Bosch, Xavier; Ramos-Casals, Manuel; Khamashta, Munther A. (2013). Drugs Targeting B-Cells in Autoimmune Diseases. Springer Science & Business Media. pp. 1–4. ISBN 9783034807067. Archived from the original on 5 November 2017.
    9. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
    10. "Rituximab Biosimilars Shown to Be Safe and Effective". www.medscape.com. Archived from the original on 15 March 2018. Retrieved 29 November 2017.
    11. "Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Retrieved 2 February 2020.
    12. "MabThera SC / Rituxan Hycela (rituximab hyaluronidase)". Roche. Retrieved 9 August 2020.
    13. "Rituxan Hycela- rituximab and hyaluronidase injection, solution". DailyMed. 3 December 2019. Retrieved 2 February 2020.
    14. Saini KS, Azim HA Jr, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA (2011). "Rituximab in Hodgkin lymphoma: Is the target always a hit?". Cancer Treat Rev. 37 (5): 385–90. doi:10.1016/j.ctrv.2010.11.005. PMID 21183282.
    15. Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, Stevens R, Shaw T (2004). "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis". N Engl J Med. 350 (25): 2572–81. doi:10.1056/NEJMoa032534. PMID 15201414.
    16. Tak PP, Kalden JR (2011). "Advances in rheumatology: new targeted therapeutics". Arthritis Research & Therapy. 13 (Suppl 1): S5. doi:10.1186/1478-6354-13-S1-S5. PMC 3123966. PMID 21624184.
    17. McGinley, MP; Moss, BP; Cohen, JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". Expert Opinion on Drug Safety. 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172.
    18. He, Dian; Guo, Rui; Zhang, Fubo; Zhang, Chao; Dong, Shuai; Zhou, Hongyu (6 December 2013). "Rituximab for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews (12): CD009130. doi:10.1002/14651858.CD009130.pub3. ISSN 1469-493X. PMID 24310855.
    19. Paul, Marla (20 May 2009). "Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus". Northwestern University News and Information. Archived from the original on 29 May 2010. Retrieved 22 May 2009.
    20. "FDA Warns of Safety Concern Regarding Rituxan in New Patient Population". U.S. Food and Drug Administration (FDA) (Press release). 18 December 2006. Archived from the original on 13 May 2009. Retrieved 29 April 2013.
    21. Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (August 2015). "Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story". Eur J Intern Med. 26 (9): 659–65. doi:10.1016/j.ejim.2015.07.021. PMID 26293834.
    22. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. (April 2005). "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura". Am. J. Hematol. 78 (4): 275–80. doi:10.1002/ajh.20276. PMID 15795920.
    23. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). "Long-term responses seen with rituximab in patients with ITP" (PDF). Community Oncology. 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4. Archived from the original (PDF) on 29 September 2007. Retrieved 18 April 2007.
    24. Shanafelt TD, Madueme HL, Wold RC, Tefferi A (2003). "Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome" (PDF). Mayo Clinic Proceedings. 78 (11): 1340–1346. doi:10.4065/78.11.1340. PMID 14601692. Archived from the original (PDF) on 13 March 2006.
    25. A. Razzaque Ahmed, M.D.; Zachary Spigelman, M.D.; Lisa A. Cavacini, Ph.D.; Marshall R. Posner, M.D. (26 October 2006). "Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin". N Engl J Med. 355 (17): 1772–1779. doi:10.1056/nejmoa062930. PMID 17065638.
    26. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA (2008). "Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients". Arch Neurol. 65 (11): 1443–1448. doi:10.1001/archneur.65.11.noc80069. PMID 18779415.
    27. "Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy". Archived from the original on 22 August 2017. Retrieved 19 October 2011.
    28. "Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis". doi:10.3998/panc.2013.20. Archived from the original on 2 May 2014. Retrieved 30 April 2014. Cite journal requires |journal= (help)
    29. Pranzatelli, M. R. (2004). "Immunologic and Clinical Responses to Rituximab in a Child with Opsoclonus-Myoclonus Syndrome". Pediatrics. 115 (1): e115–9. doi:10.1542/peds.2004-0845. PMID 15601813.
    30. Khosroshahi, A.; Wallace, Z. S.; Crowe, J. L.; Akamizu, T.; Azumi, A.; Carruthers, M. N.; Chari, S. T.; Della-Torre, E.; Frulloni, L.; Goto, H.; Hart, P. A.; Kamisawa, T.; Kawa, S.; Kawano, M.; Kim, M. H.; Kodama, Y.; Kubota, K.; Lerch, M. M.; Löhr, M.; Masaki, Y.; Matsui, S.; Mimori, T.; Nakamura, S.; Nakazawa, T.; Ohara, H.; Okazaki, K.; Ryu, J.H.; Saeki, T.; Schleinitz, N.; et al. (2015). "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease". Arthritis & Rheumatology. 67 (7): 1688–1699. doi:10.1002/art.39132. PMID 25809420.
    31. He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T, Grando SA, Zone JJ, Maverakis E (2015). "Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab". JAMA Dermatol. 151 (6): 646–50. doi:10.1001/jamadermatol.2015.59. PMID 25901938.
    32. Molloy, Eamonn S.; Calabrese, Leonard H. (2012). "Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies". Arthritis & Rheumatism. 64 (9): 3043–3051. doi:10.1002/art.34468. PMID 22422012.
    33. Burton C, Kaczmarski R, Jan-Mohamed R (2003). "Interstitial pneumonitis related to rituximab therapy". N Engl J Med. 348 (26): 2690–1, discussion 2690–1. doi:10.1056/NEJM200306263482619. PMID 12826649.
    34. "Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)" (PDF). Roche Canada. 10 November 2006. Archived from the original (PDF) on 27 March 2014.
    35. "Rituximab (marketed as Rituxan) Information". U.S. Food and Drug Administration (FDA). 23 July 2015. Archived from the original on 15 November 2009. Retrieved 15 November 2009.
    36. "Rituximab, RA and PML" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 16 September 2008. Retrieved 14 September 2008.
    37. Kriston, Levente (2009). "Challenges in Reporting Meta-analyses of Diagnostic Accuracy Studies". Annals of Internal Medicine. 150 (6): 430. doi:10.7326/0003-4819-150-6-200903170-00025. PMID 19293085.
    38. Seyfizadeh, Narges; Seyfizadeh, Nayer; Hasenkamp, J; Huerta-Yepez, S (2016). "A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections". Crit Rev Oncol Hematol. 97: 275–290. doi:10.1016/j.critrevonc.2015.09.001. PMID 26443686.
    39. Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I.; Schofield, D. J.; Lowe, D. C.; Sleeman, M. A.; Davis, D. M. (2013). "Scientists discover why a specific cancer drug is so effective". Blood. 121 (23): 4694–4702. doi:10.1182/blood-2013-02-482570. PMID 23613524. Archived from the original on 3 May 2013. Retrieved 29 April 2013.
    40. Rudnicka, D.; Oszmiana, A.; Finch, D. K.; Strickland, I.; Schofield, D. J.; Lowe, D. C.; Sleeman, M. A.; Davis, D. M. (2013). "Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity". Blood. 121 (23): 4694–4702. doi:10.1182/blood-2013-02-482570. PMID 23613524.
    41. Shaw, T. (2003). "B cell therapy for rheumatoid arthritis: The rituximab (anti-CD20) experience". Annals of the Rheumatic Diseases. 62 (90002): 55ii–59. doi:10.1136/ard.62.suppl_2.ii55. PMC 1766758. PMID 14532151.
    42. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. (2006). "The epitope recognized by rituximab". Blood. 108 (6): 1975–1978. doi:10.1182/blood-2006-04-014639. PMID 16705086.CS1 maint: multiple names: authors list (link)
    43. DrugBank DB00073 Archived 2014-01-05 at the Wayback Machine
    44. Maloney DG, Grillo-López AJ, White CA, et al. (September 1997). "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood. 90 (6): 2188–95. doi:10.1182/blood.V90.6.2188. PMID 9310469.
    45. Scott, Shane D. (1998). "Rituximab: A New Therapeutic Monoclonal Antibody for Non-Hodgkin's Lymphoma". Cancer Practice. 6 (3): 195–197. doi:10.1046/j.1523-5394.1998.006003195.x. PMID 9652253.
    46. Harrison's Principles of Internal Medicine, Longo et al. McGraw Hill Medical 2011 page 931
    47. "Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy". 29 October 2010. Archived from the original on 31 October 2010.
    48. Saporito, Bill (27 October 2014). "Hospitals Furious at Cancer-Drug Price Hikes". Time. Archived from the original on 20 October 2015. Retrieved 26 October 2015.
    49. "EU approves second indication for subcutaneous form of Roche's rituximab". Archived from the original on 7 June 2016. Retrieved 9 June 2016.
    50. "Biosimilars of Rituximab". Generics and Biosimilars Initiative. 14 April 2017. Archived from the original on 31 March 2017. Retrieved 29 April 2017.
    51. "FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 28 November 2018. Retrieved 11 November 2019.
    52. Lahiri, Diptendu; Osterman, Cynthia (2 November 2018). "Novartis abandons effort for U.S. approval of biosimilar rituximab". Reuters. Retrieved 3 November 2018.
    53. Fluge, Øystein; Rekeland, Ingrid G.; Lien, Katarina; Thürmer, Hanne; Borchgrevink, Petter C.; Schäfer, Christoph; Sørland, Kari; Aßmus, Jörg; Ktoridou-Valen, Irini (2 April 2019). "B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial". Annals of Internal Medicine. 170 (9): 585–593. doi:10.7326/M18-1451. ISSN 0003-4819. PMID 30934066.
    54. Tucker, Miriam E. (2 April 2019). "Rituximab Fails to Improve Symptoms in ME/CFS". Medscape.
    55. Castro-Marrero, Jesus; Sáez-Francàs, Naia; Santillo, Dafna; Alegre, Jose (2017). "Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: All roads lead to Rome". British Journal of Pharmacology. 174 (5): 345–369. doi:10.1111/bph.13702. PMC 5301046. PMID 28052319.
    56. Bonnan, M; Ferrari, S; Bertandeau, E; Demasles, S; Krim, E; Miquel, M; Barroso, B (2014). "Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials". Current Drug Targets. 15 (13): 1205–14. doi:10.2174/1389450115666141029234644. PMID 25355180.
    57. "Genmab.com / HuMax-CD20 (ofatumumab)". Archived from the original on 11 September 2007. Retrieved 3 December 2007.
    58. "Fc-structure". Archived from the original on 10 November 2007. Retrieved 3 December 2007.
    59. Eccles, SA (2001). "Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?". Breast Cancer Research. 3 (2): 86–90. doi:10.1186/bcr276. PMC 138676. PMID 11250751.
    60. Maverakis E, Kim K, Shimoda M, Gershwin M, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB (2015). "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity". J Autoimmun. 57 (6): 1–13. doi:10.1016/j.jaut.2014.12.002. PMC 4340844. PMID 25578468.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.